MEDEXUS PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.82 CAD | -3.70% |
|
+10.30% | -26.32% |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Medexus Third Fi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The divisionâs prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The divisionâs products include Rasuvo, IXINITY and Gleolan.
Sector
Pharmaceuticals
Calendar
2024-06-18
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.82
CAD
Average target price
3.208
CAD
Spread / Average Target
+76.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.32% | 33.86M | |
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B |
- Stock Market
- Equities
- MDP Stock
- News Medexus Pharmaceuticals Inc.
- Transcript : Medexus Pharmaceuticals Inc., Q3 2024 Earnings Call, Feb 08, 2024
